Clinical trials: Cancer, Breast
Breast Cancer
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions.
- Trial name
- NCT03697551
- Testing
- Satoreotide trizoxetan
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Ipsen
Breast Cancer
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
The aim is to determine the pharmacological and biochemical association between ribociclib exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients.
- Trial name
- LEANORA (NCT04657679)
- Testing
- Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Georgetown University
Breast Cancer
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
This two-cohort, open-label, multicenter, phase 2 study will assess the safety and efficacy of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line participants with metastatic or locally…
- Trial name
- VELVET (NCT01565083)
- Testing
- Pertuzumab, Trastuzumab, Vinorelbine
- Where
- 80 sites in United States, Brazil and 5 more
- Volunteers
- 213 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
The purpose of this research study is to study the effects of using aromatase inhibitor (AI) therapy intermittently on participants with breast cancer. AIs are a class of drugs used to treat breast cancer in postmenopausal women.
- Trial name
- NCT00549822
- Testing
- Letrozole
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
PALbociclib CoLlaborative Adjuvant Study
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early…
- Trial name
- PALLAS (NCT02513394)
- Testing
- Palbociclib, Standard Adjuvant Endocrine Therapy
- Where
- 437 sites in United States, Australia and 19 more
- Volunteers
- 5,796 people
- Sponsor
- Alliance Foundation Trials, LLC.
Breast Cancer
Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
This trial tests surgical oophorectomy (removal of ovaries) plus Tamoxifen, done at different times in the menstrual cycle, as adjuvant therapy for invasive breast cancer in 510 premenopausal women with Hormone Receptor-positive…
- Trial name
- NCT00201851
- Testing
- Tamoxifen, Surgery: Oophorectomy
- Where
- 9 sites in Morocco, Philippines and 1 more
- Volunteers
- 740 people
- Sponsor
- International Breast Cancer Research Foundation
Breast Cancer Female
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers.
- Trial name
- NCT03747042
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Texas Southwestern Medical Center
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.
- Trial name
- NCT00088829
- Testing
- paclitaxel, microarray analysis, biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Breast Cancer, Metastatic Breast Cancer
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast…
- Trial name
- NCT00404066
- Testing
- Lapatinib, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- George Albert Fisher
Breast Neoplasms, Breast Cancer
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with…
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of the Breast
- Trial name
- NCT01272141
- Testing
- Lapatinib and Everolimus
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Breast Cancer
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093795
- Testing
- Cyclophosphamide, Docetaxel, Gemcitabine
- Where
- 12 sites in United States
- Volunteers
- 4,894 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
The proposed study is being done to learn more about a particular dose of radiation treatment for breast cancer that is completed in a shorter amount of time than what has traditionally been used to treat breast cancer.
- Trial name
- NCT02700386
- Testing
- Adjuvant Hypofractionated Radiation
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Colorado, Denver
Breast Neoplasms
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and…
- Trial name
- NCT01723774
- Testing
- PD0332991, Anastrozole, Goserelin
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Washington University School of Medicine
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Breast Cancer
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
This neoadjuvant chemotherapy protocol focusing on "triple-negative" breast cancers alone will gather a foundation of primary tumor and axillary lymph nodal response to primary chemotherapy and ongoing correlated disease-free…
- Trial name
- NCT00542191
- Testing
- Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin, Definitive Surgery, Radiotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Leo W. Jenkins Cancer Center
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Breast Cancer, Adherence, Medication
Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
The purpose of this study is to explore the feasibility and acceptability of a brief, virtual, group-based cognitive-behavioral intervention for breast cancer survivors taking hormonal therapy.
- Trial name
- STRIDE (NCT03837496)
- Testing
- STRIDE, Medication Monitoring Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
The purpose of this study is to determine the clinical response rate to sorafenib when added to existing endocrine therapy in patients with advanced breast cancer.
- Trial name
- NCT00525161
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Suleiman Massarweh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.